OPHLY:OTCMKTS
Ono Pharmaceutical
4,72 $
arrow_downward
-0,42%(-0,020) 1 T
12. Okt., 16:00:00 GMT-4 · USD
search
Alle Symbole
| Symbol | Kurs | Änderung | Änderung in % |
|---|
insights_autoWichtige Einblicke für OPHLY werden generiert…
Öffnen
4,72 $
Höchstwert
4,81 $
Tiefstwert
4,72 $
Börsenwert
1,15 Bio.
Durchschn. HVol.
59.775,00
Handelsvolumen
67.563,00
52-Wochen-Hoch
5,75 $
52-Wochen-Tief
3,81 $
Beta
0,21
Aktien im Umlauf
1,50 Mrd.
Anzahl der Mitarbeiter
4206
Öffnen
4,72 $
Höchstwert
4,81 $
Tiefstwert
4,72 $
Börsenwert
1,15 Bio.
Durchschn. HVol.
59.775,00
Handelsvolumen
67.563,00
52-Wochen-Hoch
5,75 $
52-Wochen-Tief
3,81 $
Beta
0,21
Aktien im Umlauf
1,50 Mrd.
Anzahl der Mitarbeiter
4206
Nachrichtenmeldungen
Aus Webquellen und von Nachrichtenpartnern
The Motley Fool
·
vor 3 Minuten
If You Invest $5,000 in VOO Today, Here's What History Says It Could Be Worth in 20 Years
Moomoo
·
vor 6 Minuten
Dow Jones Top Company Headlines at 3 AM ET: BP Plans Strategy Update as Balance Sheet Strengthens | Monte ...
MarketBeat
·
vor 12 Minuten
Neostellar Capital (NASDAQ:NSLR) Stock Has Consensus Price Target of $14.25
Yahoo Finance
·
vor 1 Stunde
Stock Market: Will S&P 500 Open Up or Down Today?
Profil
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
Über Ono Pharmaceutical
CEOGyo Sagara | Gyo Sagara
Mitarbeiter4210
Gründungsdatum1717
HauptsitzŌsaka, Präfektur Ōsaka, Japan
Sektor-
Websiteono-pharma.com